The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cystic Fibrosis (CF) Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to infections that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.
The global Cystic Fibrosis (CF) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cystic Fibrosis (CF) Therapeutics in various end use industries. The expanding demands from the Oral drugs and Inhaled drugs, are propelling Cystic Fibrosis (CF) Therapeutics market. Pancreatic enzyme supplements, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Mucolytics segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cystic Fibrosis (CF) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cystic Fibrosis (CF) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cystic Fibrosis (CF) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cystic Fibrosis (CF) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cystic Fibrosis (CF) Therapeutics covered in this report include Vertex Pharmaceuticalsorporated, Gilead, AbbVie,, Novartis AG, F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co., AIT (Advanced Inhalation Therapies) and ALLERGAN, etc.
The global Cystic Fibrosis (CF) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Vertex Pharmaceuticalsorporated
Gilead
AbbVie,
Novartis AG
F. Hoffmann-La Roche Ltd
Alaxia
Merck & Co.
AIT (Advanced Inhalation Therapies)
ALLERGAN
AstraZeneca
Teva Pharmaceutical Industries Ltd
Alcresta
Global Cystic Fibrosis (CF) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cystic Fibrosis (CF) Therapeutics market, Segment by Type:
Pancreatic enzyme supplements
Mucolytics
Bronchodilators
CFTR modulators
Global Cystic Fibrosis (CF) Therapeutics market, by Application
Oral drugs
Inhaled drugs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cystic Fibrosis (CF) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to infections that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.
The global Cystic Fibrosis (CF) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cystic Fibrosis (CF) Therapeutics in various end use industries. The expanding demands from the Oral drugs and Inhaled drugs, are propelling Cystic Fibrosis (CF) Therapeutics market. Pancreatic enzyme supplements, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Mucolytics segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cystic Fibrosis (CF) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cystic Fibrosis (CF) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cystic Fibrosis (CF) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cystic Fibrosis (CF) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cystic Fibrosis (CF) Therapeutics covered in this report include Vertex Pharmaceuticalsorporated, Gilead, AbbVie,, Novartis AG, F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co., AIT (Advanced Inhalation Therapies) and ALLERGAN, etc.
The global Cystic Fibrosis (CF) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Vertex Pharmaceuticalsorporated
Gilead
AbbVie,
Novartis AG
F. Hoffmann-La Roche Ltd
Alaxia
Merck & Co.
AIT (Advanced Inhalation Therapies)
ALLERGAN
AstraZeneca
Teva Pharmaceutical Industries Ltd
Alcresta
Global Cystic Fibrosis (CF) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cystic Fibrosis (CF) Therapeutics market, Segment by Type:
Pancreatic enzyme supplements
Mucolytics
Bronchodilators
CFTR modulators
Global Cystic Fibrosis (CF) Therapeutics market, by Application
Oral drugs
Inhaled drugs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cystic Fibrosis (CF) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Cystic Fibrosis (CF) Therapeutics
1.1 Cystic Fibrosis (CF) Therapeutics Market Overview
1.1.1 Cystic Fibrosis (CF) Therapeutics Product Scope
1.1.2 Cystic Fibrosis (CF) Therapeutics Market Status and Outlook
1.2 Global Cystic Fibrosis (CF) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2018-2029)
1.4 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Cystic Fibrosis (CF) Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Cystic Fibrosis (CF) Therapeutics Market Size (2018-2029)
1.6.1 North America Cystic Fibrosis (CF) Therapeutics Market Size (2018-2029)
1.6.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size (2018-2029)
1.6.4 Latin America Cystic Fibrosis (CF) Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size (2018-2029)
2 Cystic Fibrosis (CF) Therapeutics Market by Type
2.1 Introduction
2.1.1 Pancreatic enzyme supplements
2.1.2 Mucolytics
2.1.3 Bronchodilators
2.1.4 CFTR modulators
2.2 Global Cystic Fibrosis (CF) Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Type (2018-2029)
3 Cystic Fibrosis (CF) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Oral drugs
3.1.2 Inhaled drugs
3.2 Global Cystic Fibrosis (CF) Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Breakdown by Application (2018-2029)
4 Cystic Fibrosis (CF) Therapeutics Competition Analysis by Players
4.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cystic Fibrosis (CF) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Cystic Fibrosis (CF) Therapeutics Market
4.4 Global Top Players Cystic Fibrosis (CF) Therapeutics Headquarters and Area Served
4.5 Key Players Cystic Fibrosis (CF) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Cystic Fibrosis (CF) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Vertex Pharmaceuticalsorporated
5.1.1 Vertex Pharmaceuticalsorporated Profile
5.1.2 Vertex Pharmaceuticalsorporated Main Business
5.1.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.1.4 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Vertex Pharmaceuticalsorporated Recent Developments
5.2 Gilead
5.2.1 Gilead Profile
5.2.2 Gilead Main Business
5.2.3 Gilead Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.2.4 Gilead Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Gilead Recent Developments
5.3 AbbVie,
5.3.1 AbbVie, Profile
5.3.2 AbbVie, Main Business
5.3.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.3.4 AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis AG Recent Developments
5.4 Novartis AG
5.4.1 Novartis AG Profile
5.4.2 Novartis AG Main Business
5.4.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.4.4 Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis AG Recent Developments
5.5 F. Hoffmann-La Roche Ltd
5.5.1 F. Hoffmann-La Roche Ltd Profile
5.5.2 F. Hoffmann-La Roche Ltd Main Business
5.5.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.5.4 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 F. Hoffmann-La Roche Ltd Recent Developments
5.6 Alaxia
5.6.1 Alaxia Profile
5.6.2 Alaxia Main Business
5.6.3 Alaxia Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.6.4 Alaxia Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Alaxia Recent Developments
5.7 Merck & Co.
5.7.1 Merck & Co. Profile
5.7.2 Merck & Co. Main Business
5.7.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.7.4 Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Merck & Co. Recent Developments
5.8 AIT (Advanced Inhalation Therapies)
5.8.1 AIT (Advanced Inhalation Therapies) Profile
5.8.2 AIT (Advanced Inhalation Therapies) Main Business
5.8.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.8.4 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 AIT (Advanced Inhalation Therapies) Recent Developments
5.9 ALLERGAN
5.9.1 ALLERGAN Profile
5.9.2 ALLERGAN Main Business
5.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.9.4 ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 ALLERGAN Recent Developments
5.10 AstraZeneca
5.10.1 AstraZeneca Profile
5.10.2 AstraZeneca Main Business
5.10.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.10.4 AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 AstraZeneca Recent Developments
5.11 Teva Pharmaceutical Industries Ltd
5.11.1 Teva Pharmaceutical Industries Ltd Profile
5.11.2 Teva Pharmaceutical Industries Ltd Main Business
5.11.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.11.4 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Teva Pharmaceutical Industries Ltd Recent Developments
5.12 Alcresta
5.12.1 Alcresta Profile
5.12.2 Alcresta Main Business
5.12.3 Alcresta Cystic Fibrosis (CF) Therapeutics Products, Services and Solutions
5.12.4 Alcresta Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Alcresta Recent Developments
6 North America
6.1 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cystic Fibrosis (CF) Therapeutics Market Dynamics
11.1 Cystic Fibrosis (CF) Therapeutics Industry Trends
11.2 Cystic Fibrosis (CF) Therapeutics Market Drivers
11.3 Cystic Fibrosis (CF) Therapeutics Market Challenges
11.4 Cystic Fibrosis (CF) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
